N. ParthasarathyR. SaksenaP. KováčD. DeShazerS. J. PeacockV. WuthiekanunH. S. HeineA. M. FriedlanderC. K. CoteS. L. WelkosJ. J. AdamoviczS. BavariD. M. WaagU.S. Army Medical Research Institute of Infectious DiseasesNational Institute of Diabetes and Digestive and Kidney DiseasesMahidol University2018-07-122018-07-122008-11-03Carbohydrate Research. Vol.343, No.16 (2008), 2783-2788000862152-s2.0-53049105779https://repository.li.mahidol.ac.th/handle/20.500.14594/18831We developed a microarray platform by immobilizing bacterial 'signature' carbohydrates onto epoxide modified glass slides. The carbohydrate microarray platform was probed with sera from non-melioidosis and melioidosis (Burkholderia pseudomallei) individuals. The platform was also probed with sera from rabbits vaccinated with Bacillus anthracis spores and Francisella tularensis bacteria. By employing this microarray platform, we were able to detect and differentiate B. pseudomallei, B. anthracis and F. tularensis antibodies in infected patients, and infected or vaccinated animals. These antibodies were absent in the sera of nai{dotless}̈ve test subjects. The advantages of the carbohydrate microarray technology over the traditional indirect hemagglutination and microagglutination tests for the serodiagnosis of melioidosis and tularemia are discussed. Furthermore, this array is a multiplex carbohydrate microarray for the detection of all three biothreat bacterial infections including melioidosis, anthrax and tularemia with one, multivalent device. The implication is that this technology could be expanded to include a wide array of infectious and biothreat agents. © 2008 Elsevier Ltd.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryArticleSCOPUS10.1016/j.carres.2008.05.021